Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|October 13, 2017
Rommelag Engineering
Canisters, bottles, tubes, ampoules, drop bottles, bellows containers, and portion packaging made of polyethylene, polypropylene, or plastic blends--the scope of Rommelag’s bottelpack machines is virtually unlimited.
Advertisement
Canisters, bottles, tubes, ampoules, drop bottles, bellows containers, and portion packaging made of polyethylene, polypropylene, or plastic blends--the scope of Rommelag’s bottelpack machines is virtually unlimited. Bottelpack Blow-Fill-Seal machines are capable of manufacturing up to 34,000 containers an hour, with filling volumes ranging from 0.04 to 10,000 mL, aseptically, and taking all the applicable pharmaceutical regulations into account.
27905 Meadow Drive, Suite 9,
Evergreen, CO 80439
mail.romus@rommelag.com
AAPS Booth #2542
Advertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement